Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Pragmatic, Open-Label Trial To Evaluate The Effect Of Three Months Of High Dose Rifapentine Plus Isoniazid Administered As A Single Round Or Given Annually In HIV-Positive Individuals

Next Previous
Trial Profile

A Randomised, Pragmatic, Open-Label Trial To Evaluate The Effect Of Three Months Of High Dose Rifapentine Plus Isoniazid Administered As A Single Round Or Given Annually In HIV-Positive Individuals

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 30 Aug 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Isoniazid (Primary) ; Rifapentine (Primary)
  • Indications Tuberculosis
  • Focus Therapeutic Use
  • Acronyms WHIP3 TB study

Most Recent Events

  • 24 Aug 2021 Primary endpoint has not been met. (TB incidence (part B), as per Results published in the Annals of Internal Medicine
  • 24 Aug 2021 Primary endpoint has been met. (Treatment completion (part A), as per Results published in the Annals of Internal Medicine
  • 24 Aug 2021 Results published in the Annals of Internal Medicine

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top